核仁形成区嗜银蛋白与非霍奇金淋巴瘤白血病的关系

• 作 者: 张宗 乔惠芬 孙俊宁 刘永锠
• 机 构: 山西省肿瘤医院血液科,山西省肿瘤医院综合技术室,山西省肿瘤医院放射生物室,山西省肿瘤医院放射生物室,
• 出 处: 白血病.淋巴瘤
• 发表日期: 2005年06期
• 关键词: AgNOR AML CML 非霍奇金淋巴瘤 白血病

目的进一步探讨非霍奇金淋巴瘤白血病(NHL-L)与核仁区嗜银蛋白(AgNORs)变化的关系。方法用银染技术检测了NHL患者49例。并用急粒细胞性白血病(AML)21例、慢粒细胞性白血病(CML)19例、非恶性血液病15例作为对照。结果三种白血病之AgNORs分别与正常对照相比差异均有统计学意义(P<0.01)。NHL-L与AML或CML相比差异具有统计学意义。临床1~2期NHL伴白血病(NHL-L1~2)、3~4期(NHL-L3~4)两组分别与NHL相比差异具有统计学意义(P<0.01)。随着病情进展,从NHL-L1到NHL-L2其AgNORs有随之上升趋势。结论AgNORs在NHL-L的预后判断上可能是一个很有用的生物指标,还可用作疗效指标以及监倥病情的复发。

Objective To investigate the relationship between non-Hodgkin’s lymphoma (NHL-L) and argyrophilic protein (AgNORs) in the nucleolar area. Methods Silver staining was used to detect 49 cases of NHL patients. 21 cases of acute myeloid leukemia (AML), 19 cases of chronic myelogenous leukemia (CML) and 15 cases of non-hematologic malignancies were used as controls. Results The differences of AgNORs between the three leukemias and normal controls were statistically significant (P <0.01). NHL-L and AML or CML compared with the difference was statistically significant. There were significant differences between NHL-L1 ~ 2 and NHL-L3 ~ 4 in clinical stage 1 ~ 2 NHL-L1 ~ 2 (P <0.01). As the disease progresses, its AgNORs have an upward trend from NHL-L1 to NHL-L2. Conclusion AgNORs may be a useful biomarker in the prognosis of NHL-L, and can be used as a curative index and the recurrence of supernumerary disease.